Date Filed | Type | Description |
06/15/2023 |
4
| Klencke Barbara (Director) has filed a Form 4 on TScan Therapeutics, Inc.
Txns:
| Granted 36,524 options to buy
@ $2.66, valued at
$97.2k
|
|
01/24/2023 |
4
| Klencke Barbara (Director) has filed a Form 4 on eFFECTOR Therapeutics, Inc.
Txns:
| Granted 28,125 options to buy
@ $0.4688, valued at
$13.2k
|
|
07/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/14/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/28/2022 |
4
| Klencke Barbara (Chief Medical Officer) has filed a Form 4 on Sierra Oncology, Inc.
Txns:
| Granted 12,250 options to buy
@ $12.15, valued at
$148.8k
|
|
11/02/2021 |
4
| Klencke Barbara (Director) has filed a Form 4 on eFFECTOR Therapeutics, Inc.
Txns:
| Granted 40,000 options to buy
@ $10.18, valued at
$407.2k
|
|
11/02/2021 |
3
| Klencke Barbara (Director) has filed a Form 3 on eFFECTOR Therapeutics, Inc. |
03/17/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/18/2020 |
4
| Klencke Barbara (Chief Development Officer) has filed a Form 4 on Sierra Oncology, Inc.
Txns:
| Bought 5,950 shares
@ $12.2201, valued at
$72.7k
Bought 3,325 shares
@ $12.2519, valued at
$40.7k
|
|
02/27/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/26/2019 |
4
| Klencke Barbara (Chief Development Officer) has filed a Form 4 on Sierra Oncology, Inc.
Txns:
| Bought 67,000 shares
@ $0.4323, valued at
$29k
Bought 54,000 shares
@ $0.4499, valued at
$24.3k
Bought 108,000 shares
@ $0.4387, valued at
$47.4k
|
|
03/05/2019 |
4
| Klencke Barbara (Chief Development Officer) has filed a Form 4 on Sierra Oncology, Inc.
Txns:
| Granted 200,000 options to buy
@ $1.96, valued at
$392k
|
|
03/07/2018 |
4
| Klencke Barbara (Chief Development Officer) has filed a Form 4 on Sierra Oncology, Inc.
Txns:
| Granted 180,360 options to buy
@ $2.36, valued at
$425.6k
|
|
03/08/2017 |
4
| Klencke Barbara (Chief Development Officer) has filed a Form 4 on Sierra Oncology, Inc.
Txns:
| Granted 70,000 options to buy
@ $1.45, valued at
$101.5k
|
|
10/04/2016 |
4
| Klencke Barbara (Chief Development Officer) has filed a Form 4 on ProNAi Therapeutics Inc
Txns:
| Granted 456,000 options to buy
@ $1.82, valued at
$829.9k
|
|
03/10/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |